Immunotherapy for Lung Cancer
Received Date : 05 Aug 2022
Accepted Date : 11 May 2023
Available Online : 07 Jun 2023
Doi: 10.37047/jos.2022-92712 - Article's Language: EN
J Oncol Sci. 2023;9(2):97-111
This is an open access article under the CC BY-NC-ND license
Lung cancer is one of the leading causes of cancer-related deaths in men and women. Similar to the approach with other cancer types, lung cancer staging is crucial in planning an effective treatment plan and predicting patient prognosis. Effective immunotherapies for patients with non-small cell lung cancer and non-genomic driver mutations are rapidly evolving. Moreover, anti-programmed death receptor- 1 (PD-1)/programmed death ligand 1 (PD-L1)-based treatments have become the first-line standard of care. Despite shortcomings, PD-L1 expression level seems currently to be a relatively reliable predictor of the clinical efficacy of treatment with anti-PD-1/PD-L1 antibodies. However, additional biomarkers are required to better personalize treatment options for these patients. This review aimed to increase awareness of lung cancer and immunotherapy treatment options, depending on patient and disease stage characteristics.
  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. [Crossref]  [PubMed] 
  2. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1-19. [Crossref]  [PubMed] 
  3. World Health Organization. The Global Cancer Observatory. Turkey Fact Sheet. 2020. [Cited: October 4, 2021]. Available from: [Link] 
  4. Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1-24. [Crossref]  [PubMed] 
  5. Markowitz SB, Levin SM, Miller A, Morabia A. Asbestos, asbestosis, smoking, and lung cancer. New findings from the North American insulator cohort. Am J Respir Crit Care Med. 2013;188(1):90-96. [Crossref]  [PubMed] 
  6. Aktaş ON, Öztürk AB, Erman B, Erus S, Tanju S, Dilege Ş. Role of natural killer cells in lung cancer. J Cancer Res Clin Oncol. 2018;144(6):997-1003. [Crossref]  [PubMed] 
  7. Metintaş M. Pleura and lung diseases due to asbestos exposure. Güncel Göğüs Hastalıkları Serisi. 2019;7(2):114-131. [Crossref] 
  8. National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. [Crossref]  [PubMed]  [PMC] 
  9. de Koning HJ, van der Aalst CM, de Jong PA, et al. reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503-513. [Crossref]  [PubMed] 
  10. The National Institute for Health and Care Excellence. Lung cancer: diagnosis and management. NICE Guideline. 2019. [Cited: October 4, 2021]. Available from: [Link] 
  11. Goldstraw P, Chansky K, Crowley J, et al; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39-51. [PubMed] 
  12. Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299-311. [Crossref]  [PubMed] 
  13. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519-525. Erratum in: Nature. 2012;491(7423):288. Rogers, Kristen [corrected to Rodgers, Kristen]. [Crossref]  [PubMed]  [PMC] 
  14. Kashima J, Kitadai R, Okuma Y. Molecular and morphological profiling of lung cancer: a foundation for "next-generation" pathologists and oncologists. Cancers (Basel). 2019;11(5):599. [Crossref]  [PubMed]  [PMC] 
  15. Planchard D, Remon J, Nowak F, Soria JC. Future genetic/genomic biomarker testing in non-small cell lung cancer. Am Soc Clin Oncol Educ Book. 2017;37:12-17. [Crossref]  [PubMed] 
  16. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase ınhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142(3):321-346. [Crossref]  [PubMed] 
  17. Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol. 2018;36(9):911-919. [PubMed] 
  18. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(5):497-530. [Crossref]  [PubMed] 
  19. Yazici O, Gürler F, Acar R, et al. EP08.01-024 multicenter real life clinical outcomes of PDL-1 tested patients with non small cell lung cancer (NSCLC) in Turkey. J Thorac Oncol. 2022;17(9):S348. [Crossref] 
  20. Lantuejoul S, Sound-Tsao M, Cooper WA, et al. PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee. J Thorac Oncol. 2020;15(4):499-519. [Crossref]  [PubMed] 
  21. Tsao MS, Kerr KM, Dacic S, Yatabe Y, Hirsch FR. IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer. 1st ed. Colorado: Editorial Rx Press; 2017.
  22. Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018;13(9):1302-1311. [PubMed]  [PMC] 
  23. Mino-Kenudson M. Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? Cancer Biol Med. 2016;13(2):157-170. [Crossref]  [PubMed]  [PMC] 
  24. Mino-Kenudsen M. Beyond PD-L1 IHC (TMB, Immune Microenvironment). J Thorac Oncol. 2019;14(10):S97-S98. [Crossref] 
  25. Greenhalgh J, Boland A, Bates V, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2021;3(3):CD010383. [Crossref]  [PubMed]  [PMC] 
  26. Chuang CH, Chen HL, Chang HM, et al. Systematic review and network meta-analysis of anaplastic lymphoma kinase (ALK) inhibitors for treatment-naïve ALK-positive lung cancer. Cancers (Basel). 2021;13(8):1966. [Crossref]  [PubMed]  [PMC] 
  27. Vasconcellos VF, Marta GN, da Silva EM, Gois AF, de Castria TB, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2020;1(1):CD009256. [Crossref]  [PubMed]  [PMC] 
  28. Stirling RG, Chau C, Shareh A, Zalcberg J, Fischer BM. Effect of follow-up surveillance after curative-ıntent treatment of NSCLC on detection of new and recurrent disease, retreatment, and survival: a systematic review and meta-analysis. J Thorac Oncol. 2021;16(5):784-797. [Crossref]  [PubMed] 
  29. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer With PD-L1 tumor proportion score ≥ 50. J Clin Oncol. 2021;39(21):2339-2349. [Crossref]  [PubMed]  [PMC] 
  30. Herbst R, De Marinis F, Giaccone G, et al. FP13.03 IMpower110: Updated OS analysis of atezolizumab vs platinum-based chemotherapy as first-line treatment in PD-L1-selected NSCLC. J Thorac Oncol. 2021;16(3):S224-S225. [Crossref] 
  31. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592-604. [Crossref]  [PubMed] 
  32. Gray J, Rodríguez-Abreu D, Powell SF, et al. FP13.02 Pembrolizumab+pemetrexed-platinum vs pemetrexed-platinum for metastatic NSCLC: 4-year follow-up from KEYNOTE-189. J Thorac Oncol. 2021;16(3):S224. [Crossref] 
  33. Robinson AG, Vicente D, Tafreshi A, et al. 97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407. J Thorac Oncol. 2021;16(4):S748-S749. [Crossref] 
  34. Socinski MA, Mok TS, Nishio M, et al. Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups. Cancer Res. 2020;80(16 Supplement):CT216. [Crossref] 
  35. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924-937. [Crossref]  [PubMed] 
  36. Nishio M, Barlesi F, Ball S, et al. 375O - Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC. Ann Oncol. 2020;31(Suppl 16):S1386-S1406. [Crossref] 
  37. Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. J Thorac Oncol. 2020;15(8):1351-1360. [Crossref]  [PubMed] 
  38. Reck M, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open. 2021;6(5):100273. Erratum in: ESMO Open. 2021;6(6):100345. [Crossref]  [PubMed]  [PMC] 
  39. Paz-Ares LG, Ciuleanu TE, Lee JS, et al. Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227. J Clin Oncol. 2021;39(15 Suppl):9016-9016. [Crossref] 
  40. Boyer M, Şendur MAN, Rodríguez-Abreu D, et al. Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥50%: Randomized, double-blind phase III KEYNOTE-598 study. J Clin Oncol. 2021;39(21):2327-2338. [Crossref]  [PubMed] 
  41. Rizvi NA, Cho BC, Reinmuth N, et al; MYSTIC Investigators. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: The MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 2020;6(5):661-674. Erratum in: JAMA Oncol. 2020;6(11):1815. [Crossref]  [PubMed]  [PMC] 
  42. Johnson ML, Cho BC, Luft A, et al. Durvalumab ± tremelimumab + chemotherapy as first-line treatment for mNSCLC: results from the phase 3 POSEIDON study. J Thorac Oncol. 2021;16(Suppl 10):S844. [Crossref] 
  43. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-1639. [Crossref]  [PubMed]  [PMC] 
  44. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-135. [Crossref]  [PubMed]  [PMC] 
  45. Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723-733. Erratum in: J Clin Oncol. 2021;39(10):1190. [Crossref]  [PubMed]  [PMC] 
  46. Mazieres J, Rittmeyer A, Gadgeel S, et al. Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials. J Thorac Oncol. 2021;16(1):140-150. [Crossref]  [PubMed] 
  47. Herbst RS, Garon EB, Kim DW, et al. Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC. J Thorac Oncol. 2021;16(10):1718-1732. [Crossref]  [PubMed] 
  48. Faivre-Finn C, Vicente D, Kurata T, et al. LBA49 - Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial. Ann Oncol. 2020;31(Suppl 4):S1142-S1215. [Crossref] 
  49. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: an update from the PACIFIC trial. J Clin Oncol. 2021;39(15 suppl):8511-8511. [Crossref] 
  50. Forde PM, Spicer J, Lu S, et al. Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. Cancer Res. 2021;81(13 Suppl):CT003. [Crossref] 
  51. Ball D, Mai GT, Vinod S, et al; TROG 09.02 CHISEL investigators. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019;20(4):494-503. [Crossref]  [PubMed] 
  52. Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373-377. [Crossref]  [PubMed]  [PMC] 
  53. Breen WG, Leventakos K, Dong H, Merrell KW. Radiation and immunotherapy: emerging mechanisms of synergy. J Thorac Dis. 2020;12(11):7011-7023. [Crossref]  [PubMed]  [PMC] 
  54. Jagodinsky JC, Harari PM, Morris ZS. The promise of combining radiation therapy with ımmunotherapy. Int J Radiat Oncol Biol Phys. 2020;108(1):6-16. [Crossref]  [PubMed]  [PMC] 
  55. Lieverse RIY, Van Limbergen EJ, Oberije CJG, et al. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC Cancer. 2020;20(1):557. [Crossref]  [PubMed]  [PMC] 
  56. Peters S, Felip E, Dafni U, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung Cancer. 2019;133:83-87. [Crossref]  [PubMed] 
  57. Schroeder SR, Leenders M, Iyengar P, de Ruysscher D. Changing equipoise in the landscape of radiation for oligometastatic lung cancer. Transl Lung Cancer Res. 2019;8(Suppl 2):S184-S191. [Crossref]  [PubMed]  [PMC] 
  58. Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019;5(9):1276-1282. [Crossref]  [PubMed]  [PMC] 
  59. Planchard D, Popat S, Kerr K, et al; ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192-iv237. Erratum in: Ann Oncol. 2019;30(5):863-870. [Crossref]  [PubMed] 
  60. Hanna NH, Robinson AG, Temin S, et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol. 2021;39(9):1040-1091. Erratum in: J Clin Oncol. 2021;39(22):2520. [Crossref]  [PubMed] 
  61. Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021;18(10):625-644. [Crossref]  [PubMed] 
  62. Su Q, Zhu EC, Wu JB, et al. Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis. Front Immunol. 2019;10:108. [Crossref]  [PubMed]  [PMC] 
  63. Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152(2):271-281. [Crossref]  [PubMed] 
  64. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607-1616. [Crossref]  [PubMed] 
  65. Langer CJ, Gadgeel SM, Borghaei H, et al; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497-1508. [Crossref]  [PubMed]  [PMC] 
  66. Antonia SJ, Villegas A, Daniel D, et al; PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929. [PubMed] 
  67. Senan S, Bahce I. Pulmonary toxicity in patients treated with immune checkpoint inhibitors and radiation. Ann Oncol. 2020;31(12):1597-1598. [Crossref]  [PubMed] 
  68. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709-717. Erratum in: J Clin Oncol. 2017;35(22):2590. [Crossref]  [PubMed]  [PMC] 
  69. Haanen JBAG, Carbonnel F, Robert C, et al; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv119-iv142. Erratum in: Ann Oncol. 2018;29(Suppl 4):iv264-iv266. [Crossref]  [PubMed] 
  70. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723. Erratum in: N Engl J Med. 2010;363(13):1290. [Crossref]  [PubMed]  [PMC] 
  71. Thompson JA. New NCCN Guidelines: recognition and management of ımmunotherapy-related toxicity. J Natl Compr Canc Netw. 2018;16(5S):594-596. [Crossref]  [PubMed] 
  72. Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology. 2017;6(10):e1344805. [Crossref]  [PubMed]  [PMC] 
  73. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4(5):560-575. [PubMed]  [PMC] 
  74. Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019;40(1):17-65. [Crossref]  [PubMed]  [PMC] 
  75. Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579-1589. [Crossref]  [PubMed]  [PMC] 
  76. Shankar B, Zhang J, Naqash AR, et al. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol. 2020;6(12):1952-1956. [Crossref]  [PubMed]  [PMC] 
  77. Shan C, Li X, Zhang J. Progress of immune checkpoint LAG-3 in immunotherapy. Oncol Lett. 2020;20(5):207. [Crossref]  [PubMed]  [PMC] 
  78. Morgensztern D, Chaudhry A, Iannotti N, et al. RELATIVITY-104: First-line relatlimab (RELA) + nivolumab (NIVO) with chemotherapy vs nivo with chemotherapy in stage IV or recurrent non-small cell lung cancer (NSCLC): A phase II, randomized, double-blind study. Ann Oncol. 2021;32(Suppl 5):S949-S1039. [Crossref]